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Abstract: A meeting organised by the Academy of Pharmaceutical Sciences focussed on the challenges
of developing medicines for older adults. International experts discussed the complexity introduced
by polypharmacy and multiple morbidities and how the risk–benefit ratio of a medicine changes as
an individual ages. The way in which regulatory authorities are encouraging the development of
age-appropriate medicines was highlighted. Examples were provided of the difficulties faced by the
older population with some medicinal products and suggestions given as to how the pharmaceutical
scientist can build the requirements of the older population into their development of new medicines,
as well as improvements to existing ones.
Keywords: polypharmacy; multiple morbidities; ageing; pharmaceutical sciences; product
development; SIMPATHY
1. Introduction
The Academy of Pharmaceutical Sciences (APS, the professional body for pharmaceutical scientists
in the UK) hosted a meeting on the challenges of age-related medicines as part of the APS@FIP
Conference in Glasgow, UK, on 7 September 2018. Alpana Mair (Effective Prescribing and Therapeutics,
Scottish Government), Sven Stegemann (University of Graz and Lonza) and Diana van Riet-Nales
(Quality Department, Medicines Evaluation Board, the Netherlands) spoke at the meeting chaired by
Mine Orlu (UCL School of Pharmacy).
There is an increasing awareness that an individual’s response to disease and their ability
to metabolise medicines changes with age. As a result, there have been a number of initiatives
to encourage the development of medicines specifically for children. However, the changing
world demographics due to increasing life expectancy [1], with increasing numbers of older people
(the so-called ‘silver tsunami’), means that companies should start developing medicines designed for
the specific needs that are prevalent in the older population. The APS meeting, organised by the APS
Age-Related Medicines Focus Group, explored some of the current challenges and opportunities in
developing these medicines. The meeting heard from some of the EU’s leading experts on the recent
developments in this exciting area of the pharmaceutical sciences.
Pharmaceutics 2019, 11, 172; doi:10.3390/pharmaceutics11040172 www.mdpi.com/journal/pharmaceutics
Pharmaceutics 2019, 11, 172 2 of 11
2. What or Who is Considered as Old?
Discussing challenges of developing medicines for ‘older adults’ implies that the patient
population of ‘old’ or ’older’ is clearly defined. The dictionary definition mentions concepts such
as ‘having lived for a relatively long time’ or ‘belonging to a remote or former period in history’ [2].
On an individual basis, we might think ourselves that we are getting old when we need to take many
medicines, start to make noise after any movement of our bodies or when we regard staying up to
11.30 pm as “living wildly”.
This already suggests that it is very difficult to define ‘old’ in the context of human ageing.
Chronological age, physical age and cognitive age may or may not be coincident. A number of
different biomarkers, including telomere length or DNA/chromosomal damage, taken in combination,
have been suggested as more objective measures to determine our actual biological age, but are
measures requiring a lot of effort. In addition, assessment tools such as muscle mass or grip strength are
easier measures and have been suggested to evaluate an individual’s functional ability [3]. Interestingly,
people with a higher biological age at 38 years age faster than people with a lower biological age
(i.e., the gap remains over their lifetime) [4].
Determining the age of an individual more objectively is an important aspect of healthcare
provision. There is a good consensus today that lifestyle plays a key role in the ageing trajectory.
In the Whitehall II cohort study, the investigators found a correlation between unhealthy lifestyles
(low physical activity, smoking and alcohol consumption) in middle age and disability (defined as
reporting difficulties with mobility and instrumental / basic activities of daily living) when people
grew older (the odds ratio for 2–3 unhealthy lifestyles and disability was 2.69 (95% confidence interval
= 2.26–3.19)) [5]. Surprisingly, there was no correlation between the low consumption of fruit and
vegetables and disability.
Overall, increasing wealth and advances in medical and pharmaceutical sciences are contributing
to more years of healthy life as well as longer life expectancy. A German study found that on average,
today’s 75-year-olds are cognitively fitter and happier than the 75-year-olds of 20 years ago. These
findings support statements that the rise in life expectancy is accompanied by an increase in years
of health, at least for 60- to 80-years old (comparison of data from the Berlin Aging Study (BASE)
collected in 1993 [6] and the repeat BASE II study in 2014 [7]).
3. Multiple Morbidities
The huge differences in the health trajectories of individuals and their poor correlation with
chronological age is a major challenge in considering someone ‘old’ from a healthcare perspective.
There is evidence that the incidence of acquiring and accumulating chronic diseases increases with
increasing age. A recent study showed that multimorbidity, defined by WHO [8] as the co-occurrence
of two or more chronic medical conditions in one person, affects >30% of those 45–64 years old,
rising to >65% in those 65–84 years old and >82% in those >85 years old [9]. In addition, the incidence
appears to be increasing across all age groups beyond 18 years and is becoming more prevalent at an
earlier age [10]. Barnett et al. have also reported that multimorbidities can occur 10–15 years earlier in
individuals from the most deprived areas [11]. Multimorbidity is a worldwide phenomenon and is
only loosely correlated with the per capita national gross domestic product of the country [12].
Older adults with multimorbidity experience a high symptom burden associated with increased
healthcare utilisation, frequent visits to the emergency department, hospitalisation, admissions
to nursing homes, and a reduced quality of life [13]. The authors used the Memorial Symptom
Assessment Scale (MSAS) [14] to study community-dwelling individuals aged more than 74 years
old in Sweden. They determined that pain was the symptom with the highest prevalence, frequency,
severity, distress and symptom burden, with a lack of energy and dry mouth affecting half of the
study group. In conclusion, they found that individuals with poor vision, a likelihood of depression
and illnesses of the digestive system were most at risk of a high symptom burden and might need
age-specific guidelines for appropriate medication management.
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A study in the Netherlands and Belgium investigated the therapeutic burden and identified four
‘daily life domains’ with associated aspects that impacted patients with multiple morbidities [15].
These were: organisation of care (waiting and travelling times, attitude of healthcare practitioners
(HCPs), etc.); medication (side effects, multiple medications and how to use them, absence of a review
to determine if they are still relevant, etc.); patient’s role (accepting condition and treatment as routine,
depression/hopelessness, resistance to visits by a doctor or to treatment, etc.); and impact on daily life
(taking medicines when travelling, being on a special diet, limitations imposed by side effects, etc.).
These findings highlight the importance of the disease and therapeutic burden on patient experience
and perception.
Shippee et al. [16] had previously developed a functional, patient-centric model which addressed
what they termed the ‘cumulative complexity’ faced by patients with multiple morbidities. This model
described the balance between patient workload demands (related to the treatment, self-care and
life in general) and the patient’s capacity to handle the demands (including functional morbidity,
financial/social resources and literacy) as a result of the increasing disease and therapeutic burden.
This model provides further evidence that a single disease–single medicine concept might not be
applicable to multimorbid patients with polypharmacy.
4. Polypharmacy
As the number of comorbidities increases, so does the number of medicines for the patient.
Such multiple medication use may be referred to as polypharmacy. Many definitions of this exist:
in some domains, polypharmacy is defined as the intake of more than one medicinal product when
the medication burden exceeds a certain threshold; however, the most common definition is the intake
of five or more medicines [17]. All this implies that the intake of two to four (or even more) medicines
may be referred to as polypharmacy.
It is important to note that polypharmacy can be both appropriate and inappropriate.
The label “inappropriate” applies when polypharmacy can be linked to a number of potentially
undesirable effects:
• There is an increase in the patient’s frailty linked to the number of their medicines. Frailty increases
by 1.5× with five or more medicines and 2× with 10 or more [18] (note that in this reference,
the term hyperpolypharmacy is coined for ≥10 medicines).
• The patient’s adherence to taking their medicines declines with polypharmacy [19,20].
• The risk of adverse drug reactions (ADRs) increases with the number of medicines being
taken in older patients, with the risk for severe ADRs also being linked to age and frailty [21].
Pimohamed et al. [22] surveyed the medicines and the classes thereof most likely to cause ADRs
leading to hospital admissions. The top five (medicine/class and % of ADRs caused) were:
non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin (29.6%); diuretics (27.3%); warfarin
(10.5%); angiotensin-converting enzyme (ACE) inhibitors (7.7%); and antidepressants (7.1%).
In order to better manage polypharmacy, Mair described the EU SIMPATHY (Stimulating
Innovation Management of Polypharmacy and Adherence in The Elderly) consortium (of which
the Scottish Government is the lead) and the Scottish Government’s approach to address
appropriate polypharmacy.
The SIMPATHY consortium was set up to explore how healthcare management programmes can
be implemented to improve medication safety and prevent patient harm by addressing the appropriate
use of multiple medicines (polypharmacy).
The results were published in guidelines on polypharmacy and how to reduce the adverse
impacts [23,24]. The guidelines define appropriate and inappropriate polypharmacy (Table 1) and
stress the importance of multidisciplinary healthcare provider teams working with the patients and
the need to break down barriers between the healthcare professionals.
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Table 1. Criteria for appropriate and inappropriate polypharmacy.
Appropriate Polypharmacy Inappropriate Polypharmacy
All medicines are prescribed for the purpose of
achieving specific therapeutic objectives that have
been agreed with the patient.
There is no evidence-based indication, the indication
has ended, or the dose is unnecessarily high.
Therapeutic objectives are being achieved or there is a
reasonable chance they will be achieved in the future.
One or more medicines fail to achieve the therapeutic
objectives they are intended to achieve.
Medicine therapy has been optimised to minimise the
risk of ADRs.
One or the combination of several medicines cause
unacceptable ADRs or put the patient at an
unacceptably high risk of such ADRs.
The patient is motivated and able to take all
medicines as intended.
The patient is not willing or able to take one or more
medicines as intended.
Mair described the seven-step plan to review the medications of a patient with polypharmacy to
achieve appropriate prescribing as recommended in the guidelines. The plan takes a holistic view on
the patient’s health situation and tries to balance the clinical needs and priorities, while at the same
time using the patient’s wishes as the guiding objective (Table 2).
Table 2. Seven-step plan for polypharmacy medicine review as detailed in the SIMPATHY guidelines.
Step Objective Action
1 Aims Identify the objectives based on what matters to the patient
2 Need Identify necessary medicine therapies
3 Need Identify unnecessary medicine therapies
4 Effectiveness Are the therapeutic objectives being achieved?
5 Safety Does the patient have or are they at risk of ADRs?
6 Cost-effectiveness Is the medicine therapy cost-effective?
7 Patient-centric consideration Is the patient willing and able to take the medicine therapy as intended?
The importance of step 1, focussing on what the patient wants, was illustrated by an example
where a patient with a history of cardiovascular disease, who was already taking a statin, ACE inhibitor,
beta-blocker, a diuretic and paracetamol for multiple morbidities, then had gabapentin prescribed by
their doctor without any discussion. The effect of this was to make the patient light-headed and they
suffered a fall which hospitalised them and had a very negative effect on their quality of life.
Another example was a patient who had poorly controlled asthma, but could not think about
managing this until they had received treatment for the pain they were in from a separate morbidity.
Necessary medicines, which are identified in step 2, might be those that have essential replacement
functions (such as thyroxine) or prevent rapid symptomatic decline (e.g., medicines for Parkinson’s
disease or heart failure). Unnecessary therapies might be those for temporary indications, with higher
than usual maintenance doses or which have limited benefit and are evaluated in step 3.
The effectiveness of the existing therapy is evaluated in step 4. If the therapeutic objectives are
not being achieved, the therapy can be re-evaluated and intensified with the existing medicine therapy
or new risks to benefits of a specific medicine therapy analysed dependent on their morbidity.
The concept of ‘Number Needed to Treat’ (NNT), a measure of how many patients will benefit
from the specific medication (calculated from the average number benefiting with a control in a clinical
trial), can be used to assess the effectiveness of a drug therapy, including whether the specific patient
will benefit from the therapy. A value of 1 indicates that all patients will benefit, while a higher value
means less chance of achieving the desired outcomes [25].
A review of drug–disease and drug–drug interactions from published data and from observations
by and answers to specific questions from the patient is evaluated in step 5. The guidelines also offer
various charts summarising the risk of interactions.
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Part of this step also includes sick day review cards providing information to the patient as to
which medicines they should stop taking if they are unwell (with vomiting/diarrhoea or fevers, sweats
and shaking).
Step 6 considers the economic factors and whether there are alternative therapies, with an
appropriate risk–benefit–convenience balance, that are more cost-effective.
In the final step, the patient’s willingness and ability to use the medicines is considered in order
to assure the desired outcomes. Examples here might be the patient needing retraining on how to
use their asthma inhaler, ensuring that the patient and their caregiver understand the outcome of the
review, and/or determining whether the patient is willing and/or able to make the recommended
lifestyle changes (e.g., giving up smoking).
5. Regulatory Initiatives to Ensure Better Medicines for Older People
This section focusses on the activities of the European Medicines Agency (EMA). See [26–28] for
further information.
Regulatory authorities have to balance the risks against the benefits for the putative new, generic
or hybrid medicines based on the information with which they have been provided in the relevant
application. Coupling this information with the Good Manufacturing Practice (GMP) certification of
the manufacturing site to ensure the quality of the medicinal products allows them to grant a marketing
authorisation (or variation) for the relevant products. The summary of product characteristics (SmPC),
package leaflet (PL) and product label provide details of the patients for whom the medicine is intended
based on clinical trials. The patient populations to which the medicine is being prescribed are often
much wider in terms of age and multimorbidity than those studied in the clinical trials related to
the application.
Older adults might respond quite differently to the medication compared to younger adults in
view of age-related changes in pharmacokinetics, pharmacodynamics and multiple morbidities [29].
Only for a few (mostly recently authorised) medicines is it stated that some of the products in the
medicine portfolio are specifically intended for a specific subset of the population, e.g., children, adults
with swallowing difficulties, etc.
Regulatory authorities have recognised that the needs of ‘special’ patient populations have to be
considered during the medicine development process. Starting with the paediatric populations, older
adults have been identified as another population requiring better tailored medicines. There are
a number of similarities between paediatrics and the older population; for example, both have
metabolisms and physiologies which differ from the majority of adults, both can have difficulty
swallowing and both may require special dosing considerations. On the other hand, whereas the
paediatric population and some of the older population have caregivers, a significant proportion
of the older population may live independently and hence be responsible for their own medication
management. The older population is also much more likely to have multiple morbidities and
use polypharmacy.
Recognition by the regulatory authorities led to the initiative to develop the EMA Geriatric
Strategy [30,31] and to review the existing legislative framework with respect to the ageing population,
as well as to “identify the gaps in regulatory and scientific knowledge and take appropriate measures
to tackle them” [30] (note that there is no specific geriatric regulation). The measures have included
the organisation of a workshop on geriatric medicine [32] and the provision of scientific advice during
product development. In the latter case, the emphasis is on formulations and pharmaceutical product
design which suit the needs of older adults to improve effectiveness. De Spiegeleer et al. [28] have
suggested that the impact of current regulatory initiatives needs to be monitored, and if they are not
successful in leading to better medicines for the older population, then the idea of geriatric investigation
plans (GIPs; similar to paediatric investigation plans (PIPs)) may need to be considered.
The regulatory initiatives also focus on the better representation of older adults as a targeted
patient population. The ICH E7 [33] guideline provides directions on the inclusion of older adults
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in clinical studies to address their routine underrepresentation in clinical trials where the medicines
are intended for the general population [31]. This guidance suggests that data should be presented
for various age groups (for example, <65-, 65–74-, 75–84- and >85-year-olds) to assess the consistency
of the treatment effect and safety profile for these patients with the randomised patient populations
included in the major phase III clinical trials. EMA guidance on what defines frailty [34,35] emphasises
that age is not the only consideration in assigning and assessing individuals in such trials, and frailty
needs also to be taken into account.
With the introduction of the ICH Q8 [36], covering pharmaceutical development, the definition of
pharmaceutical quality was extended beyond the technical aspects by emphasising the requirement
that “the product should be designed to meet patients’ needs and the intended product performance”.
The needs of older adults and especially multimorbid patients with polypharmacy will almost certainly
differ from those of younger patients. Therefore, more consideration has to be given during medicine
development to the pharmacokinetic performance of the medicine, the ability of the patient to handle
and use the medicine, and the medicine’s impact on the patient’s health and quality of life in situations
of multiple morbidities and polypharmacy.
In accordance with the increasing patient focus, the EMA have recently published their draft
reflection paper on the pharmaceutical development of medicines for use in the older population [37]
(consultation closed 30 January 2018). Consistent with the adopted guidance for paediatrics,
the document intends to summarise the existing data and knowledge on pharmaceutical medicinal
product design for older adults. Information from the literature (e.g., [38,39]), post-marketing data,
discussions with stakeholders on practical issues and a gap analysis on how existing marketing
authorisations are not fully meeting the needs of older patients were reviewed. As a reflection paper,
the document is not intended to provide guidance, but to provide useful information on developing
medicinal products suitable for use in the older population and to promote discussion on the topics
addressed [37].
In order to suitably acknowledge older people’s needs in pharmaceutical development, it is
essential to respect that knowledge on the specific needs of older people may not be readily available
among medicine developers in industry who are commonly trained in nonmedical sciences. Therefore,
the draft paper includes an annex describing the general, sensory, motor and (patho-)physiologic
issues prominent in older people and requiring specific attention in the (pharmaceutical) development
of the medicine. For example, the older population may:
• experience difficulties in administering certain dosage forms (swallowing of tablets and capsules
due to dysphagia, administering eye drops and patches, etc.);
• struggle to open certain packaging or dosage containers or handle dosing devices (due to poor
handling capabilities);
• have higher risk for medication errors due to visual impairments (e.g., not being able to
differentiate one white tablet from another) or therapeutic complexity;
• not be able to read and/or understand instructions and to appropriately follow these in daily life
(due to poor eyesight, health literacy, cognitive abilities or lack of caregiver assistance).
The reflection paper also mentions the need to modify dosage forms to facilitate dosing through an
enteral feeding tube or to fragment the medication to reduce the dosage or to mix with food to make it
easier to swallow. However, all these modifications would need verification by industry before they can
be included in the SmPC/PL; i.e., before information on these modifications becomes available to the
user of the medicine. Validation might require longer in-use shelf lives to allow caregivers to prepare
medicines to be left over weekends or holiday periods. Otherwise, these modifications are considered
as being for off-label use, meaning they are the sole responsibility of the healthcare professional.
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6. What Do Older Patients Expect from Pharmacotherapy?
Adlai Stevenson (an American politician) once said ‘in the end, it’s not the years in your life
that count; it’s the life in your years’. Everyone’s personal goal should be to achieve ‘healthy ageing’,
defined as “the process of developing and maintaining functional ability which enables wellbeing in
old age” [8].However, there can be a mismatch between what healthcare professionals and caregivers
regard as a healthy life (with a focus on body functioning, vital energy, resilience and care support)
and what individuals regard as their ‘quality of life’, which also encompasses a positive life balance,
future life perspective, social participation, active daily organisation, environmental support and relief
from loneliness [40]. A focus purely on health matters can miss the attention needed to ensure an
individual’s overall quality of life, especially as quality of life is becoming a more important goal
for older patients. The importance of an individual’s quality of life is highlighted by data from
Belgium on the demand for physician-assisted dying, which increased from 3.4% of the surveyed
population in 2007 to 5.9% in 2013, with the proportion of requests granted rising from 1.9% to 4.6%.
Among the reasons given were ‘low expected quality of life’ and ‘loss of dignity’ [41]. The issue of
physician-assisted dying inevitably raises the question as to what constitutes ‘dead’, and the case of
Jahi McMath in the US still being alive (albeit in a coma) after being declared dead by physicians is
one of the most publicised cases on this matter [42].
Trewby et al. [43] highlighted the difference between a physician’s view on what constitutes a
health benefit and a patient’s expectations in a study based upon a hypothetical cholesterol-lowering
medicine. Three hundred subjects were studied using a written questionnaire and an interview.
They were split into three groups consisting of those who had had just been discharged from a coronary
care unit, those who were taking cardioprotective medicines but had no history of myocardial infarction,
and those with no history and who were not taking cardioprotective medicines. The threshold of
expected benefit versus the inconvenience of having to take a medicine long-term was 20%, 20% and
30% absolute risk reduction, respectively, for the three groups. These expected benefit figures need
to be compared with the likely benefit, which is only <5% over a five-year period, even though it is
statistically significant. The authors concluded that if the patient is told of the likely benefit, they may
not be inclined to take the medicine.
The complexity of interacting dosing regimens for an individual with multiple morbidities
was illustrated for a patient suffering pain and taking three painkillers), a proton pump inhibitor
(for stomach protection), Wobenzym (a combination of plant-derived enzymes, for joint swelling),
a treatment for muscle cramps and prophylaxis for deep vein thrombosis. The dosing regimen
necessary to comply with the various dosing schedules would require the patient to take one or more
medicines at four different times in the morning, at three different times during each of the afternoon
and evening and a final dose at 0300 h; a seemingly impossible regime to which to adhere.
Van Riet-Nales gave examples on how existing medicinal products are not meeting the needs
of the older population. In work on the need to subdivide large tablets, which otherwise may be
difficult to swallow, van Riet-Nales et al. [44] studied the use of three commercial tablet-splitter devices
and the accuracy and precision with which they produced uniform tablet fragments when applied
to 500 mg paracetamol tablets. Some tablet splitters gave very bad results, and subdivision by hand
gave fragments which met the regulatory requirements best. The latter option may not be available
to older persons as they may not have adequate dexterity (the results reported were achieved by a
healthy 24-year-old). The authors concluded that HCPs need to appreciate that tablet division may
lead to inaccurate dosing and that regulatory authorities should take appropriate actions to ensure the
accuracy of splitter devices and, where feasible, reduce the need for their use in the first place.
In a second example [45], individuals over 70 years old were interviewed about their medicines.
Ninety-five percent reported problems and, in some cases, described the way in which they got around
these issues (e.g., they might resort to using a sharp implement to open packaging or store medicines
that look alike separately). While most of the issues were ones of inconvenience, 5% of the problems
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in combination with the patient’s management strategy were deemed sufficiently serious to cause
moderate or severe clinical deterioration.
Drumond et al. [39] conducted a literature review on the clinical evidence for the
patient’s appropriateness, acceptability, usability or preference for pharmaceutical preparations.
They summarised their findings and concluded that little attention is being given to these elements
when designing a medicinal product. The implications, in particular where the patient is responsible
for their own medication, are inappropriate use of the medicines or lack of adherence.
ICH Q8 [36] introduced the concept of the quality target product profile (QTPP) to define the
requirements for a medicinal product during development. Stegemann [46] has highlighted the
need to link this to the ‘real-world disease’ patient. In the case of the older population, factors
such as their ability to handle the medicine packaging, cope with the dosing regimen (bearing in
mind polypharmacy) and to distinguish one product from another should be taken into account.
The advances in medicinal product design (such as controlled release products or requirements to
take products before, with or after meals to optimise pharmacokinetics) might not be respected by
patients due to prior learning. A patient simply sees a product that looks like one they have always
taken and will use it and administer it in the same way. The consequence can be that they crush a
controlled release product to make it easier to take, thereby destroying its release profile, or take all of
their medicines at the same time as they are then more likely to remember to take them.
The pharmaceutical scientist needs to consider how the product they are developing will be
used. They need not only to work to a QTPP, but also to a ‘targeted patient profile’. It may not be
necessary to tailor the product to a particular age group, as with some thought, they could evolve
‘traditional design’ to ‘universal design’ [46]. For example, the round screw cap on medication bottles
could be replaced by a triangular one to make it easier to be opened by patients with a poor grip.
Likewise, tablet appearance could be improved by using high-contrast imprints rather than embossing
to allow identification by patients with poor eyesight. A recently published book, ‘Developing Drug
Products in an Aging Society: From Concept to Prescribing’ [47], provides further practical guidance.
In a similar message to that given by Mair on improving polypharmacy, Stegemann [46] suggests
that patient-centric medicinal products can be achieved by interdisciplinary collaboration between the
clinical, pharmaceutical, regulatory and marketing experts. This would obviously have input from
inclusion of the older population in the clinical trials and involve listening to their experiences using
the medicinal products. The same message is given in the (draft) EMA reflection paper.
7. Conclusions
Life expectancy is increasing, and even though chronological age does not necessarily correlate
with ill health, the incidence of multiple morbidities, which can start in early adulthood, increases with
age. The availability of new medicine therapies plays an important role in an individual achieving
healthy ageing and maintaining a good quality of life, as well as addressing the impact of an ageing
population on the demands of caregivers and society overall. However, the challenges of polypharmacy,
medicine adherence and the suitability of medicines for the older population need to be tackled.
A holistic approach where academia, industry, HCPs and patients work together to understand the
patient’s needs and abilities and how they can best be addressed in the provision of appropriate
medication is essential. Especially, the pharmaceutical scientist has an important role to ensure
that medicinal products, delivery systems and dosing regimens meet the patient’s and caregiver’s
requirements and do not just add to their burden. Clinicians should realize that lack of efficacy or
side effects may not relate to the medicine itself, but rather to the dosage form, formulation/strength
and/or the selected trademark, as patients may be unable to use certain products as intended.
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